Cargando…

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Canrong, Liu, Yang, Yang, Yueying, Zhang, Peng, Zhong, Wu, Wang, Yali, Wang, Qiqi, Xu, Yang, Li, Mingxue, Li, Xingzhou, Zheng, Mengzhu, Chen, Lixia, Li, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102550/ https://www.ncbi.nlm.nih.gov/pubmed/32292689 http://dx.doi.org/10.1016/j.apsb.2020.02.008

Ejemplares similares

Furin: A Potential Therapeutic Target for COVID-19
por: Wu, Canrong, et al.
Publicado: (2020)

A natural DYRK1A inhibitor as a potential stimulator for β‐cell proliferation in diabetes
por: Zheng, Mengzhu, et al.
Publicado: (2021)

A natural inhibitor of kidney-type glutaminase: a withanolide from Physalis pubescens with potent anti-tumor activity
por: Wu, Canrong, et al.
Publicado: (2017)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
por: Zhou, Shilin, et al.
Publicado: (2023)

The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia
por: Jin, Sanshan, et al.
Publicado: (2022)

Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2
por: Fan, Shiyong, et al.
Publicado: (2020)

Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1
por: Zheng, Mengzhu, et al.
Publicado: (2017)

PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids
por: Wu, Yanli, et al.
Publicado: (2022)

Drug discovery targeting SARS-CoV-2 membrane fusion
por: Yang, Kailu, et al.
Publicado: (2023)

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
por: Wang, Lin, et al.
Publicado: (2021)

Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
por: Wang, Zhonglei, et al.
Publicado: (2021)

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
por: Pang, Xiaojing, et al.
Publicado: (2023)

Discovery of 4′-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor
por: Wu, Qianqian, et al.
Publicado: (2022)

Computational Approaches in Preclinical Studies on Drug Discovery and Development
por: Wu, Fengxu, et al.
Publicado: (2020)

Drug Discovery Strategies for SARS-CoV-2
por: Shyr, Zeenat A., et al.
Publicado: (2020)

Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design
por: Sinha, Meetali, et al.
Publicado: (2021)

SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery
por: Royster, Austin, et al.
Publicado: (2023)

Structure Based Affinity Maturation and Characterizing of SARS-CoV Antibody CR3022 against SARS-CoV-2 by Computational and Experimental Approaches
por: Yu, Wei, et al.
Publicado: (2022)

Drug Discovery in Low Data Regimes: Leveraging a Computational Pipeline for the Discovery of Novel SARS-CoV-2 Nsp14-MTase Inhibitors
por: Nigam, AkshatKumar, et al.
Publicado: (2023)

2636. Discovery of Spike Identification (SpiID) Nanobody Panel for SARS-CoV-2 Vaccine Development
por: Li, Qi, et al.
Publicado: (2023)

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics
por: Pérez-Vargas, Jimena, et al.
Publicado: (2023)

Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
por: Wang, Haofeng, et al.
Publicado: (2023)

Computer-aided discovery, design, and investigation of COVID-19 therapeutics
por: Chang, Chun-Chun, et al.
Publicado: (2022)

Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates
por: Wang, Yi, et al.
Publicado: (2021)

Bioinformatics resources for SARS-CoV-2 discovery and surveillance
por: Hu, Tao, et al.
Publicado: (2021)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening
por: Li, Daixi, et al.
Publicado: (2021)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
por: Yu, Wei, et al.
Publicado: (2021)

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
por: Fidan, Ozkan, et al.
Publicado: (2022)

Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2
por: Shen, Min, et al.
Publicado: (2020)

Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
por: Li, Wei, et al.
Publicado: (2017)

Impaired lung regeneration after SARS‐CoV‐2 infection
por: Shao, Hongxia, et al.
Publicado: (2020)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
por: Xia, Binbin, et al.
Publicado: (2023)

Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors
por: Jawad, Bahaa, et al.
Publicado: (2022)

Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline
por: Lau, Edmond Y., et al.
Publicado: (2021)

Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design
por: Shao, Hai Ping, et al.
Publicado: (2023)

Structure‐based drug discovery facilitates future painkiller development
por: Li, Yuqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nqlk65f1vs3va5qol4bth15s2s